Laquinimod efficacy in relapsing-remitting multiple sclerosis: how to understand why and if studies disagree

by Cutter, Gary R., Knappertz, Volker, Sasson, Nissim, Ladkani, David
Published 2016

Establishing Long-Term Efficacy in Chronic Disease: Use of Recursive Partitioning and Propensity Score Adjustment to Estimate Outcome in MS

by Goodin, Douglas S., Jones, Jason, Li, David, Traboulsee, Anthony, Reder, Anthony T., Beckmann, Karola, Konieczny, Andreas, Knappertz, Volker
Published 2011

Causes of Death among Commercially Insured Multiple Sclerosis Patients in the United States

by Goodin, Douglas S., Corwin, Michael, Kaufman, David, Golub, Howard, Reshef, Shoshana, Rametta, Mark J., Knappertz, Volker, Cutter, Gary, Pleimes, Dirk
Published 2014

Cause of death in MS: long-term follow-up of a randomised cohort, 21 years after the start of the pivotal IFNβ-1b study

by Goodin, Douglas S, Ebers, George C, Cutter, Gary, Cook, Stuart D, O'Donnell, Timothy, Reder, Anthony T, Kremenchutzky, Marcelo, Oger, Joel, Rametta, Mark, Beckmann, Karola, Knappertz, Volker
Published 2012

Incidence and course of depression in multiple sclerosis in the multinational BEYOND trial

by Schippling, Sven, O’Connor, Paul, Knappertz, Volker, Pohl, Christoph, Bogumil, Timon, Suarez, Gustavo, Cook, Stuart, Filippi, Massimo, Hartung, Hans-Peter, Comi, Giancarlo, Jeffery, Douglas R., Kappos, Ludwig, Goodin, Douglas S., Arnason, Barry
Published 2016

Challenges and opportunities in designing clinical trials for neuromyelitis optica

by Weinshenker, Brian G., Barron, Gerard, Behne, Jacinta M., Bennett, Jeffery L., Chin, Peter S., Cree, Bruce A.C., de Seze, Jerome, Flor, Armando, Fujihara, Kazuo, Greenberg, Benjamin, Higashi, Sayumi, Holt, William, Khan, Omar, Knappertz, Volker, Levy, Michael, Melia, Angela T., Palace, Jacqueline, Smith, Terry J., Sormani, Maria Pia, Van Herle, Katja, VanMeter, Susan, Villoslada, Pablo, Walton, Marc K., Wasiewski, Warren, Wingerchuk, Dean M., Yeaman, Michael R.
Published 2015